<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105959</url>
  </required_header>
  <id_info>
    <org_study_id>RIST4721-102</org_study_id>
    <nct_id>NCT04105959</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model</brief_title>
  <official_title>A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristea Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristea Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of
      RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects
      Using a Standardized Blister Model
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute neutrophil count in blister fluid at 24 hours post-blister formation compared to placebo</measure>
    <time_frame>Blister formation to Hour 24</time_frame>
    <description>Blister fluid will be harvested at 24, 30, and 36 hours post-blister formation and neutrophil count will be assessed at each time point and compared to placebo control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute neutrophil count in blister fluid at 30 hours post-blister formation compared to placebo</measure>
    <time_frame>Blister formation to Hour 30</time_frame>
    <description>Blister fluid will be harvested at 24, 30, and 36 hours post-blister formation and neutrophil count will be assessed at each time point and compared to placebo control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute neutrophil count in blister fluid at 36 hours post-blister formation compared to placebo</measure>
    <time_frame>Blister formation to Hour 36</time_frame>
    <description>Blister fluid will be harvested at 24, 30, and 36 hours post-blister formation and neutrophil count will be assessed at each time point and compared to placebo control</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>RIST4721 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIST4721 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIST4721</intervention_name>
    <description>RIST4721 oral solution</description>
    <arm_group_label>RIST4721 150mg</arm_group_label>
    <arm_group_label>RIST4721 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral solution</description>
    <arm_group_label>RIST4721 150mg</arm_group_label>
    <arm_group_label>RIST4721 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male, with Fitzpatrick skin types 1 to 3

          -  Subject is aged between 18 to 55 years, inclusive

          -  Subject has a body mass index (BMI) of 18 to 32 kg/m2, inclusive

          -  Healthy as determined by a responsible physician, based on medical evaluation

          -  Must be willing to use birth control as indicated

        Exclusion Criteria:

          -  Subject is known to have immune deficiency or is immunocompromised

          -  Subject has had a recent acute infection or chronic infection

          -  Subject has a known or suspected allergy or contraindications to cantharidin (blister
             induction method), RIST4721 or any component of the study drug

          -  Clinically relevant history of abnormal physical or mental health (including [but not
             limited to], neurological, psychiatric, endocrine, cardiovascular, respiratory,
             gastrointestinal, hepatic, or renal disorder)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blister</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

